Destiny Pharma PLC Directorate Change (0610S)
June 21 2018 - 1:00AM
UK Regulatory
TIDMDEST
RNS Number : 0610S
Destiny Pharma PLC
21 June 2018
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma appoints Nick Rodgers as Non-Executive
Director
Brighton, United Kingdom - 21 June 2018 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), announces the
appointment of Nick Rodgers as an independent Non-Executive
Director with immediate effect.
Nick Rodgers has considerable Board experience in both public
and private growth companies, particularly those in the life
science sector, as well as a background as a successful corporate
financier and investment banker. Nick is currently chairman of
SEHTA, one of the largest health technology networking
organisations in the UK. Prior to this, he was non-executive
director and then chairman of fully listed Oxford Biomedica plc, a
leading gene-based biopharmaceutical company, from 2004 until 2016.
Previously. Nick headed up both the Life Science and Corporate
Finance department at Evolution Beeson Gregory (now Investec)
advising many life science listed companies from 1989 until
2003.
Sir Nigel Rudd, Chairman of Destiny Pharma commented:
"We are very pleased to announce Nick's appointment to our
Board. His experience of guiding growth companies, and in
particular those in the life science sector will be invaluable as
Destiny Pharma expands its activities and continues to advance its
lead drug candidate, XF-73, through clinical development."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Philip Nicholas
(Nick) Rodgers, aged 59 years, has been a director of the following
companies during the five years preceding the date of this
announcement:
Current Past
Nick Rodgers Financial Limited Oxford BioMedica
plc
Productiv Limited
Productiv Property Ltd
Productiv Technology Ltd (dormant)
The Proving Factory Ltd (dormant)
South East Health Technologies
Alliance Ltd
Alcuris Limited
Zapinamo Limited
Interactive Me Limited
There is no further information to be disclosed pursuant to Rule
17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the World
Health Organisation (WHO) and the United Nations, as well as the G7
and the G20 countries. For further information, please visit
https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABRGDLCSDBGIG
(END) Dow Jones Newswires
June 21, 2018 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024